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This review aims to summarize the technique and clinical applications of CT perfusion (CTp) of head and neck cancer. The most
common pathologic type (90%) of head and neck cancer is squamous cell carcinoma (HNSCC): its diagnostic workup relies on CT
andMRI, as they provide an accurate staging for the disease by determining tumour volume, assessing its extension, and detecting
of lymph node metastases. Compared with conventional CT and MRI, CTp allows for obtaining measures of tumour vascular
physiology and functional behaviour, and it has been demonstrated to be a feasible and useful tool in predicting local outcomes in
patients undergoing radiation therapy and chemotherapy and may help monitor both treatments.
1. Introduction
Head andneck cancers represent about 5%of allmalignancies
newly diagnosed each year. Squamous cell carcinoma is
the most common histology, accounting for about 90% of
these tumours. Head and neck squamous cell carcinomas
(HNSCC) arise from the mucosa of the upper aerodigestive
tract and are linked by common characteristics includ-
ing a male-predominant presentation and a multifactorial
etiopathogenesis. Historically tobacco and alcohol assump-
tion are the most important risk factors while human papil-
loma virus (HPV) exposure is an emerging cause, particularly
common in the oropharynx subsite and with a better clinical
outcome [1].
Most head and neck patients present in a locally advanced
stage with a poor prognosis. In this setting various strategies
have been tried to improve outcomes of the two main
standard treatments (surgery and radiotherapy). Concomi-
tant chemoradiation treatment has become the standard of
care in the unresectable locally advanced disease and as
organ preservation strategy [2]. Induction polychemotherapy
(given before radiotherapy with or without concomitant
chemotherapy) has been extensively investigated on the effort
of improving overall survival by reducing the incidence of
distant metastasis [3–5]. Despite the wide literature on this
topic, this approach cannot be considered a standard of care
yet and needs further data. Finally the overexpression of
epidermal growth factor receptor in HNSCC is more than
90% and a correlation between this feature and a worse prog-
nosis was found. Cetuximab, a monoclonal antibody against
epidermal growth factor receptor, showed significant efficacy
in locoregional control of disease and in overall survival
either in the curative setting [6] or in the recurrent/metastatic
HNSCC [7].
Given all these new therapeutic approaches, there
remains the fact that a subset of patients obtain a major or
complete response, especially from induction chemotherapy
and target therapy, and we do not have predictive markers to
anticipate this and to personalize the therapeutic strategy in
order to improve outcomes or reduce toxicity.
In the clinical practice cross-sectional imaging integrates
endoscopic evaluation of HNSCC providing information
about the local invasion of the tumour into the surrounding
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structures as well as the regional spread of the disease, as both
have an impact on treatment and prognosis.
The traditional evaluation of response to treatment is
based on modification of tumour dimensions which is
unidimensional for the universally recognized Response
Evaluation Criteria in Solid Tumour (RECIST) [17].
The assessment of tumour volume changes after treat-
ment by CT may be used as an objective and reproducible
technique for therapymonitoring, with good correlationwith
histology [18].
Furthermore CT-determined tumor volume is a strong
predictor of local and locoregional outcome of laryngeal
carcinoma [19].
However cross-sectional imaging techniques provide
only morphologic assessment and do not tell us anything
about the tumour biology.
The knowledge about the cellularity or the perfusion of
a tumour may help in the differentiation of the biological
behaviour during and after treatment of lesions having the
same histologic type [20].
CT perfusion (CTp) has recently been used to obtain
measures of tumour vascular physiology and hemodynamic.
In contrast to the logarithmic relation between signal inten-
sity and concentration of paramagnetic contrast medium of
dynamic contrast enhancement MRI (DCE-MRI), the main
advantage of CTp is the linear relationship between con-
trast concentration and attenuation in CT, which facilitates
quantitativemeasurement of perfusion parameters [21]. Also,
CTp advantages include high spatial resolution and wide
availability, having the use of ionizing radiation, need of
iodinated contrast medium injection, and relatively limited
coverage as its major limitations.
2. CTp Technique
CTp is a theoretical tool able to quantify, through mathe-
matical models and dedicated software, the “real” perfusion
of tissues. The first technical requirement is the execution of
repeated CT scans of the volume being analysed during and
after intravenous administration of a fast bolus of iodinated
contrast medium, to allow the study of the density variations
over time [22]. The density measured by CT in the unit of
volume (voxel), expressed in Hounsfield units (HU), reflects
the contrast agent within the blood vessels and the contrast
agent which has moved to the interstitial space due to passive
diffusion [23].
The selection of the arterial input through the placement
of a region of interest (ROI) on an artery allows obtaining
a time-density curve of the artery, expressed in HU. This
is then compared with the time-density curve of the tissue
being analysed in order to distinguish between the quantity
of contrast agent within the blood vessels (vascular com-
partment) and the quantity present in the interstitium (extra
vascular/extra cellular compartment) [23].
Some studies demonstrated that the use of internal
carotid artery (ICA) or external carotid artery (ECA) ipsilat-
eral or contralateral to the tumour as the arterial input has
no significant effect on CTp calculation of HNSCC [24, 25].
Tawfik et al. recommend the use of ICA because of the lower
risk of partial volume effects correlated with its larger caliber
and its course, almost perpendicular to the axial plane [24].
Various kinetic models can be used to calculate the
distribution of contrast agent in the different compartments
through the estimation of the perfusion parameters. In some
of these models the analysis is performed using the single-
compartment or double-compartmentmethodwhich respec-
tively describes the vascular and extravascular compartments
as single or separate compartments [26].
The deconvolution method uses arterial and tissue time-
density curves to calculate the impulse residue function
(IRF), a theoretic tissue curve obtained assuming that the
contrast agent is not diffusible and its concentration in the
tissue is linearly dependent on the input arterial concentra-
tion when the blood flow is constant [26].
Most papers published about CTp in the study of HNSCC
used the deconvolution based software which generates the
following perfusion parameters [23, 27].
(i) Blood flow (BF), expressed in mL/min/100 g of tissue,
is the flow rate of blood through the vasculature in
tissue region. BF includes flow information from large
vessels, arterioles, capillaries, and venules as well as
arteriovenous shunts, which are more common in
neoplastic tissue than in healthy tissue.
(ii) Blood volume (BV), expressed in mL/100 g of tissue,
represents the volume of blood that flows within
vasculature in a tissue region.
(iii) Mean transit time (MTT), expressed in seconds,
represents the mean time the blood takes to pass
through the microvasculature from the arterial to the
venous end. MTT is inversely correlated to BF.
(iv) Permeability-surface products (PS), expressed in
mL/min/100 g of tissue, measure the product
between the permeability and the total surface area
of capillary endothelium in a unit mass of tissue
(usually 100 g of tissue). It is considered as a surrogate
marker of immature leaky vessels which are more
common in neoplastic tissue.
Clinical interpretation of CTp is based on a qualitative
analysis and a quantitative analysis. Qualitative analysis
involves the analysis of the colour maps generated by the
software for each perfusion parameter. Each pixel of the CT
images is attributed a colour which represents the numerical
value of perfusion parameter calculated for that pixel and the
colour scale is chosen by the operator in order to maximize
the differences between areas having different perfusion.
Quantitative analysis involves the interpretation of
numerical values of perfusion, which the software calculates
for the area bounded by the ROI placed over the tumour
representing the mean of the numerical values of each voxel
included in the ROI [23].
Similar to CTp studies of other tumour sites [28], Petralia
et al. found a good inter- and intraobserver agreement when
CTp data were analysed by differently experienced readers,
especially for BF, BV, and MTT [25]. The lower and more
variable agreement observed for PS probably depends on
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Table 1: CTp parameters obtained during and after radiotherapy and induction chemotherapy showing as valid predictions in monitoring
the treatment.
Author Cancer Treatment Number ofpatients
Predictive
parameters
𝑃 value Type of study
Truong et al. [8] Primary HNSCC Radiotherapy 15 BF
0.046 Prospective
BV 0.053





SCCA of the upper








Chemoradiotherapy 20 BV 0.01 Prospective
Notes: SCCA: squamous cell carcinoma; HNSCC: head and neck squamous cell carcinoma; BF: blood flow; and BV: blood volume.
the fact that its calculation, being reliant on prolonged
scanning, is likely more affected by the cumulative effects of
small motions than the other parameters which derive from
first-pass scanning [25].
Over the past decade several studies investigated the
role of CTp both in monitoring and predicting short-
term and long-term response to organ-preserving treatments
in HNSCC, though different end points were considered:
disease-free survival in some case [16] and tumour volume
reduction in others [9, 13, 14].
3. Monitoring during and after Treatment
In the clinical routine endoscopic examination integrated
by biopsy and cross-sectional imaging represents the gold
standard for therapy monitoring of HNSCC.
Few studies (Table 1) investigated the value of CT-
determined tumour perfusion in this specific clinical setting
in a similar way to what demonstrated for tumours located
in other body regions. This is based on the theory that
changes produced by radiotherapy and chemotherapeutic
agents on tumour vascularity can be identified by changes
in CTp measured tumour perfusion. Treatment, specifically,
induced reduction of microvessels inside the tumour could
be identified as a decrease of BV values while a decrease
of BF could indicate a reduction of low resistance flow
arteriovenous shunts in the microvasculature. The reduction
of hyperpermeable capillary bed could be expressed with a
decrease of PS values [29] (Figure 1).
In a small group of 9 patients treated with induction
chemotherapy Gandhi et al. [10] found a positive correlation
between BV pretreatment lesion values and the tumour
response assessed by endoscopy. They also found that a
decrease ≥ than 20% in BV values after 3 weeks of therapy
is able to predict a reduction of cancer volume greater than
50%.
Petralia et al. [9] confirmed the relevance of CTp param-
eters in monitoring the response to the therapy.They found a
significant correlation between the percent change in BV and
BF values and the percent reduction of tumour volume after
3 cycles of induction chemotherapy. Their results appear to
be more reliable since they use, as response quantification,
tumour volume assessed by CT instead of the endoscopy
standard which is an operator-dependent technique.
Serial fluctuations in perfusion parameters of HNSCC
during a course or radiotherapy were prospectively evaluated
by Truong et al. [8], by using CTp to provide informa-
tion about the periodical changes in tumour oxygenation
produced by radiotherapy. Pretreatment tumour BF was
higher in patients who achieved locoregional control (LRC)
compared with those with locoregional failure (LRF) (𝑃 =
0.004), consistent with the findings of Hermans et al. [12].
Furthermore, authors demonstrated that an increase in BF
during the first two weeks of radiotherapy is able to predict
LRC, with a decrease in both groups after 6 weeks of radio-
therapy compared with the values at the baseline scanning,
suggesting that a higher BF in tumour tissue at the baseline
and during the early course or radiotherapy predicts a better
tumour control.
Interestingly Sˇurlan-Popovicˇ et al. [11], in a series of 24
patients with locally advanced HNSCC, demonstrated that
the modifications of CTp parameters during the course of
treatment might predict tumour response to cisplatin-based
chemoradiotherapy.
In particular responders presented a significant reduction
of BF values (p 0,04) after 40Gywhich wasmore pronounced
after 70Gy (p 0,01) and a significant reduction of BV values
after 40Gy with a plateau after 70Gy (p 0,04). MTT and PS
values showed nonsignificant modifications.
On the contrary in nonresponders BF, BV, and PS values
showed a nonsignificant increase after 40Gy.
The possible explanation given by the authors to these
findings is that the dynamics in CTp parameters are mainly
related to the cytotoxic effects of radiotherapy to the vascular
endotheliumwhich is more effective than the little antivascu-
lar action of cisplatin-based chemotherapy [11].
In an attempt to explain the increase of perfusion parame-
ters values observed in nonresponders, authors hypothesized
that ionizing radiation therapymay produce the upregulation
of VEGF which promotes survival of endothelial cells in




Figure 1: Squamous cell carcinoma of hypopharynx in a responder patient: CT scan (a) obtained before chemotherapy shows the lesion
involving the right piriform sinus. On the same section, functional maps of BF (b), BV (c), MTT (d), and PS (e) are automatically generated by
the software, showing the values calculated in each pixel of the image in a color scale. CT scan obtained in the same patient after chemotherapy
and radiotherapy showing a complete disappearance of the tumour (f).
residual tumour tissue and consequently radiation resistance
[30].
4. Prediction of Response to
Radiotherapy and Chemotherapy
The rationale of the potential role of CTp in predicting
response to nonsurgical therapies is that it is substantially
influenced by tissue perfusion and local oxygen delivery. The
oxygen supply to a tissue is governed by its perfusion and the
arterial oxygen concentration. It is conceivable that higher
levels of BF and BV may correlate with better oxygen/drug
delivery and therefore may predict the response to radiation
therapy or chemotherapy.
Theoretically, a CTp study performed prior to the begin-
ning of therapy could identify patients with poorly perfused
tumours likely to demonstrate a bad response to chemora-
diotherapy, thus allowing them to be directed to alternative
treatments [29].
Thus, in recent years, some studies appeared in the
literature dealing with this topic (Table 2).
In a series of 105 patients with HNSCC treated with
definitive radiotherapy, some associated with adjuvant
chemotherapy,Hermans et al. [12] found that CTpparameters
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Table 2: Results for the prediction of response to radiotherapy and chemotherapy based on the pretreatment tumour volume and the
perfusion-associated parameters.
Author Cancer Number ofpatients Predictive parameters 𝑃 value Type of study
Hermans
et al. [12] Primary HNSCC 105 Median perfusion value 0.01 Prospective
Zima et al.
[13]
SCCA of the upper
aerodigestive tract
17 BF <0.03 Prospective
BV <0.004
Bisdas et al.
[14] Advanced oropharynx SCCA 19 BF, BV, PS, MTT <0.001 Prospective
Petralia et al.
[9]
SCCA of the upper
aerodigestive tract 25 BV 0.015
Bisdas et al.
[15]
Primary SCCA of oral cavity,
oropharynx, hypopharynx




SCCA of the upper
aerodigestive tract
84 BF, PS <0.000 Prospective
BF-BV mismatch 0.01
Notes: SCCA: squamous cell carcinoma; HNSCC: head and neck squamous cell carcinoma; BF: blood flow; BV: blood volume; PS: permeability surface area
product; MTT: mean transit time; and CP: capillary permeability surface area product.
(a) (b)
(c) (d)
Figure 2: Squamous cell carcinoma of the oropharynx in a nonresponder patient. The functional maps of BF (a), BV (b), MTT (c), and PS
(d) are automatically generated by the software, showing low BF and BV values within the lesion.
are independent predictors of local control together with T
stage. In particular patientswith a lowperfusion pretreatment
value showed a statistically significantly higher local failure
rate than those with a high perfusion value (𝑃 < 0.05),
presumably due to a more extensive degree of hypoxia in
low-perfused tumour and therefore characterized by low
radiosensitivity (Figure 2).
Similarly, in a study of 17 patients, Zima et al. [13]
demonstrated that elevated pretreatment values of BF (𝑃 <
0.03) and BV (𝑃 < 0.004) CTp parameters showed a signif-
icant correlation with response to induction chemotherapy
evaluated endoscopically.
Bisdas et al. [14] confirmed these results showing
correlation between radiological response after induction
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chemotherapy and CTp parameters at baseline while just
a weak correlation with pretreatment tumour volume was
found.With these findingsCTpperfusion parameters seemed
to outperform the morphologic characteristics, being signif-
icantly different (𝑃 ≤ 0.002) between responders and nonre-
sponders with high BF, BV, and PS and low MTT correlated
with a better tumour response, presumably reflecting better
tumour oxygenation. The authors concluded their paper
highlighting the role of CTp as a noninvasive, inexpensive,
and widely accessible diagnostic tool, able to improve the
choice of organ preservation treatment regimens in order to
maximize the therapeutic efficacy [14].
In the paper by Petralia et al. [9] only baseline tumour BV
was significantly lower (𝑝 0, 015) in nonresponder compared
to responders to induction chemotherapy.They found a trend
to correlation between baseline tumour BV and high tumor
volume reduction assessed by CT [21].
Bisdas et al. [15] assessed whether CTp may predict
outcome in 21 chemoradiated patient with oral cavity,
oropharynx, and hypopharynx SCC after surgical excision:
they applied a new analysis on the region of interest-
derived CTp values, namely, the maximum BF, BV, and
PS, as well as the minimum MTT values, trying to avoid
the considerable intratumoral variation covered with mean
values. Both mean perfusion values and BFmax, BVmax, and
BSmax were significantly different between patients with and
without tumour recurrence (𝑃 < 0.04). Also, the authors
underline the predictive value of PS and MTT. In particular
they found a relative risk of recurrence about 14 time higher
in patients with lower than the median BSmean values, which
is apparently in contrast with the results of other studies
demonstrating a significantly shorter disease-free survival
in patients with high intratumoral microvessel density [31].
According to the authors these findings confirm the absence
of any clear relationship between microvascular density and
PS values [32]. On the other hand the predictive role of MTT
values may be attributed in part to leaky tumour vessels,
which lead to improved oxygenation [15].
The same authors [16], in a large series of 84 patients with
advanced HNSCCwho underwent CTp prior to concomitant
chemoradiotherapy, found that BF and PS values were signif-
icantly higher in patients who had local failure (𝑃 ≤ 0.02).
Furthermore a simultaneous visual evaluation of the BF
and the BV parametric maps showed that the presence of a
mismatch (>30% of the examined lesion extent) between the
colour-encoded maps correlates with shorter life expectance
(𝑃 = 0.01) and smaller recurrence-free survival (𝑃 = 0.03).
This approach is based on the rational that a considerable
mismatch, more evident in locally advanced tumours, may
indicate a heterogeneous pattern of vascularisation, which
may lead to a cascade that influences cellular phenotypes and
presents with therapy resistance [33].
5. Conclusions
All the preliminary results of previous studies show that
elevated CT perfusion parameters are statistically correlated
to a better response to radiotherapy and chemotherapy and
prove that tissue oxygenation may also influence the spread
of chemotherapy agents and a higher radiosensitivity.
BV and BF have clearly emerged as the most significative
CTp parameters as they may predict response to radiation
therapy and chemotherapy and may help monitor both
treatments.
PS and MTT parameters are insufficiently predictive of
the response compared with BV and BF: only one paper
highlighted their achievable effectiveness [15].
It must be also considered that published studies consid-
ered different end points and most of them correlated their
findings with short-term follow-up.
Large-scale studies examining the long-term predictive
value of baseline CTp studies in patient treated both with
neoadjuvant chemoradiation or chemoradiation with cura-
tive intent might help in tailoring the therapy regimen on
individual basis. As an instance, the possibility to identify
earlier a failed response to induction chemotherapymay help
avoid this step during the therapeutic treatment plan.
Therefore, a more standardized technique is hopeful in
order to achieve reproducible and comparable method across
different institutions.
Future integrated applications with PET-CT findings or
dual-energy CT may enable more understanding of the
biologic behaviour of the tumour in vivo,making theCTp one
of the potential cornerstone of biologic imaging of HNSCC.
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